Gilead Sciences, Inc. (GILD.SN)
| Previous close | 65.55 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 57.39 - 57.39 |
| 52-week range | 57.39 - 65.55 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 71.564B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 17.55 |
| EPS (TTM) | 3.27 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 14 June 2024 |
| 1y target est | N/A |
Business WireGilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., April 30, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Simply Wall St.Gilead Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Gilead Sciences ( NASDAQ:GILD ) First Quarter 2024 Results Key Financial Results Revenue: US$6.69b (up 5.3% from 1Q...
Business WireFDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
FOSTER CITY, Calif., April 26, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of
